Cambridge, United States
GC Therapeutics, branded with the slogan "A Path to SuperCells™ Therapies," leverages synthetic biology to engineer patient-derived stem cells into any cell type with notable efficiency and scalability. Founded in 2019, this biotechnology and pharmaceutical entity optimizes cell programming with unparalleled speed—up to 100 times faster than traditional methods. It has validated its technology in various applications and developed SuperCells™ tailored for specific diseases.
The company's core technology was innovatively developed in Professor George Church’s laboratory at Harvard Medical School, showcasing a lineage of cutting-edge research. GC Therapeutics recently secured a $65.00M Series A investment on 01 October 2024, led by the esteemed investor Global Brain. This infusion of capital signals strong investor confidence in their unique approach to disrupting the cell therapy landscape. With no specific headquarters mentioned, the company embodies a global reach in the field of advanced therapeutic solutions.
